WhaleCreep

Fairmount Funds Management LLC 13F holdings, Q4 2024

Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →

Fairmount Funds Management LLC disclosed 17 US equity positions worth $1.0bn in its Q4 2024 13F filing. The largest position was AXSM at 12.4% of the reported book, followed by NUVALENT INC and SYRE. Against the Q3 2024 filing, it opened 3 new positions, added to 1 and reduced 3 among the top 17 holdings.

← Q3 2024 · Q1 2025 →

What did Fairmount Funds Management LLC own in Q4 2024? Top 17 positions

#StockSectorWeightValueSharesΔ sharesvs Q3 2024
1 AXSM AXSOME THERAPEUTICS INC Healthcare 12.4%$124.3m1,468,983 -38% reduced
2 NUVALENT INC 10.3%$103.1m1,317,664 -22% reduced
3 SYRE SPYRE THERAPEUTICS INC 9.3%$93.5m4,018,101 0% held
4 APGE APOGEE THERAPEUTICS INC Healthcare 9.2%$92.8m2,048,647 0% held
5 SRRK SCHOLAR ROCK HLDG CORP Healthcare 8.4%$84.8m1,962,953 – new
6 ELVN ENLIVEN THERAPEUTICS INC Healthcare 7.2%$72.1m3,202,798 0% held
7 VRDN VIRIDIAN THERAPEUTICS INC Healthcare 6.6%$66.1m3,445,813 0% held
8 ORKA ORUKA THERAPEUTICS INC Healthcare 6.5%$65.4m3,371,922 5% added
9 DNTH DIANTHUS THERAPEUTICS INC Healthcare 5.9%$58.9m2,700,691 0% held
10 COGT COGENT BIOSCIENCES INC Healthcare 4.8%$48.6m6,225,641 0% held
11 KINIKSA PHARMACEUTICALS INTL 4.3%$43.4m2,194,341 -32% reduced
12 DAWNGBX DAY ONE BIOPHARMACEUTICALS INC 3.9%$39.3m3,103,448 0% held
13 CATBUSD ASTRIA THERAPEUTICS INC 3.2%$31.8m3,554,129 0% held
14 ANAB ANAPTYSBIO INC Healthcare 2.4%$24.1m1,816,466 – new
15 BCAX BICARA THERAPEUTICS INC 2.2%$22.4m1,284,169 0% held
16 IKT INHIBIKASE THERAPEUTICS INC 2.0%$19.9m6,125,000 – new
17 ZBIO ZENAS BIOPHARMA INC 1.5%$15.5m1,892,806 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.